参考文献
[1]Franchini M,Marano G, Pati I, et al.Emicizumab for the treatment of Haemophilia A:a narrative review [J].Blood ransfus,2019,17:223-228.
[2]Young G.How I treat childen with Haemophilia and inhibitors[J].British Journal of Haematology,2019,186:400-408.
[3]肯尼斯·柯尚斯基.威廉姆斯血液学[M].9版.陈竺,陈赛娟主译.北京:人民卫生出版社,2018:1922-1989.
[4]Cafuir L, Krus-Jarres R, Mancuso M E, et al.Emicizumab for hemophilia A without inhibitors [J].Expert Review of Hematology, 2019,12(7):515-524.
[5]Eichler H, Angchaisuksiri P, Kavakli K, et al.Concizumab restores thrombin generation Potential in patients with haemophilia:Pharmacokinetic/pharmacodynamic modeling results of cocizumab phase 1/1b data [J].Haemophilia, 2019, 25:60-66.
[6]Lauritzen B, Olling J, Abel K L, et al.Administration of recombinant FⅦa(rFⅦa)to oncizumab-dosed monkeys is safe, and cocizumab does not affect the potency of rFⅦa in hemophilic rabbits [J].J Thromb Haemost, 2019, 17:460-469.
[7]Koji YAda, Keiji Nogami.SPoTlight on emicizumab in the management of Hemophilia A Patient selection and special considrations[J].Journal of BLood Medicine,2019,10:171.(https://www.daowen.com)
[8]赵晓艾,刘陕西,李飞,等.血友病凝血因子抗体的诊断及影响因素研究[J].中国实验血液学杂志,2011, 19(4):971-974.
[9]刘陕西,刘义国.一种用于治疗血友病的复方血友胶囊及其制备方法[P].中国专利:10130047X,2014.
[10]Yang, Shaofang Ge, Miao Liu, et al.A Preliminary Study of Age and Sex of People with Hemophilia[J].Health, 2017, 9: 401-408.
[11]Ljung R, Auerswald G,Benson G,et al.Inhibitors in Haemophilia A and B:Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients[J].Eur J Haematol,2019,102(2):111-122.
[12]Youg G, Mahlangu J N.Extended half-life clotting facor concentrates:results from published clinical trials [J].Haemophilia, 2016,22(Suppl5):25-30.